Literature DB >> 10941945

The cost diary: a method to measure direct and indirect costs in cost-effectiveness research.

M E Goossens1, M P Rutten-van Mölken, J W Vlaeyen, S M van der Linden.   

Abstract

From a societal perspective long-term clinical trials or follow-up studies should preferably not only include an evaluation of the health effect for the patient, but also an economic evaluation. In order to yield comprehensive medical and nonmedical resource use data, we at least partly depend on respondents' recall for collecting these costing data. A patient cost diary was developed in order to estimate total resource use, expenses, and lost production due to illness and treatment. We applied the cost diary in two randomized clinical trials evaluating the cost-effectiveness of behavioral rehabilitation in 205 fibromyalgia and chronic low back pain patients. The use of the diary was evaluated, studying the feasibility, the influence of the period of data collection on the results, and some aspects of validity. Eighty-five percent of the patients completed at least one diary and in total 68% of the diaries were returned. Although the results for the three alternative periods of data collection (keeping the diary 1 week every month, 2 weeks every 2 months, or a full year) were not significantly different, they were only moderately correlated. Finally, self-reported specialist care contacts were generally in agreement with data from an insurance company. However, for physiotherapy contacts there were differences between the self-reported and insurance data. This study shows how the cost diary might be used successfully in cost-effectiveness studies.

Entities:  

Mesh:

Year:  2000        PMID: 10941945     DOI: 10.1016/s0895-4356(99)00177-8

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  116 in total

Review 1.  Evidence from cost-effectiveness research.

Authors:  Katia Noyes; Robert G Holloway
Journal:  NeuroRx       Date:  2004-07

2.  [Conceptual and methodological basics of cost assessments in rheumatology].

Authors:  J Ruof; J L Hülsemann; T Mittendorf; J-M von der Schulenburg; H Zeidler; S Merkesdal
Journal:  Z Rheumatol       Date:  2004-10       Impact factor: 1.372

Review 3.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

4.  Costs of inflammatory bowel disease in Germany.

Authors:  Renee Stark; Hans-Helmut König; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects.

Authors:  V Rabenda; C Manette; R Lemmens; A-M Mariani; N Struvay; J-Y Reginster
Journal:  Osteoporos Int       Date:  2006-06-24       Impact factor: 4.507

6.  How Chiropractors began working in a Community Health Centre in Ottawa.

Authors:  Neil B Baskerville; Dirk Keenan
Journal:  J Can Chiropr Assoc       Date:  2005-03

7.  The cost-effectiveness of a treatment-based classification system for low back pain: design of a randomised controlled trial and economic evaluation.

Authors:  Adri T Apeldoorn; Raymond W Ostelo; Hans van Helvoirt; Julie M Fritz; Henrika C W de Vet; Maurits W van Tulder
Journal:  BMC Musculoskelet Disord       Date:  2010-03-26       Impact factor: 2.362

8.  An explorative cost-effectiveness analysis of school-based screening for child anxiety using a decision analytic model.

Authors:  Ellin Simon; Carmen D Dirksen; Susan M Bögels
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-03-29       Impact factor: 4.785

9.  Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.

Authors:  A Boonen; D van der Heijde; R Landewé; F Guillemin; M Rutten-van Mölken; M Dougados; H Mielants; K de Vlam; H van der Tempel; S Boesen; A Spoorenberg; H Schouten; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

Review 10.  Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors.

Authors:  Katia Noyes; Eric A Singer; Edward M Messing
Journal:  Curr Opin Urol       Date:  2008-09       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.